Liver-Directed immunotherapy aims to boost Body's cancer fight before surgery
NCT ID NCT07172282
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This early-phase study tests whether a new drug, Nelitolimod, can safely boost the immune system's ability to fight colorectal cancer that has spread to the liver. Ten adults will receive the drug directly into the liver through a special catheter before their scheduled surgery. The main goal is to see if this approach is safe and does not delay or prevent the planned liver operation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RJ Zuckerberg
RECRUITINGLake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.